The KEGG enrichment analysis revealed that the molecular pathways underlying the anti-HCC effects of the nitazoxanide drug might involve pathways in cancer, PI3K-Akt signaling pathway, MAPK signaling pathway, proteoglycans in cancer, EGFR tyrosine kinase inhibitor resistance, apoptosis, hepatitis B, ErbB signaling pathway, microRNAs in cancer, etc. In spite of the fact that the PI3K–AKT signaling pathway regulates a wide range of cellular processes, its abnormal activation promotes the development of HCC (Rahmani et al., 2020). The gene discussed is PPIB; the disease is Hepatitis.